JP2023542279A5 - - Google Patents

Info

Publication number
JP2023542279A5
JP2023542279A5 JP2023512665A JP2023512665A JP2023542279A5 JP 2023542279 A5 JP2023542279 A5 JP 2023542279A5 JP 2023512665 A JP2023512665 A JP 2023512665A JP 2023512665 A JP2023512665 A JP 2023512665A JP 2023542279 A5 JP2023542279 A5 JP 2023542279A5
Authority
JP
Japan
Prior art keywords
sequence
promoter
composition according
seq
polynucleotide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023512665A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023542279A (ja
Filing date
Publication date
Priority claimed from CN202010705069.XA external-priority patent/CN113952472A/zh
Application filed filed Critical
Publication of JP2023542279A publication Critical patent/JP2023542279A/ja
Publication of JP2023542279A5 publication Critical patent/JP2023542279A5/ja
Pending legal-status Critical Current

Links

JP2023512665A 2020-07-21 2021-07-20 眼疾患の処置のための組成物および方法 Pending JP2023542279A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202010705069.XA CN113952472A (zh) 2020-07-21 2020-07-21 用于治疗眼部疾病的组合物和方法
PCT/IB2021/000509 WO2022018518A1 (en) 2020-07-21 2021-07-20 Compositions and methods for the treatment of eye diseases

Publications (2)

Publication Number Publication Date
JP2023542279A JP2023542279A (ja) 2023-10-06
JP2023542279A5 true JP2023542279A5 (cg-RX-API-DMAC7.html) 2024-07-26

Family

ID=79459955

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023512665A Pending JP2023542279A (ja) 2020-07-21 2021-07-20 眼疾患の処置のための組成物および方法

Country Status (7)

Country Link
US (1) US20230321281A1 (cg-RX-API-DMAC7.html)
EP (1) EP4185319A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023542279A (cg-RX-API-DMAC7.html)
CN (2) CN113952472A (cg-RX-API-DMAC7.html)
AU (1) AU2021312379A1 (cg-RX-API-DMAC7.html)
CA (1) CA3186826A1 (cg-RX-API-DMAC7.html)
WO (1) WO2022018518A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3191540A1 (en) * 2020-09-02 2022-03-10 4D Molecular Therapeutics Inc. Codon optimized rpgrorf 15 genes and uses thereof
WO2026032020A1 (zh) * 2024-08-06 2026-02-12 北京中因科技有限公司 Aav介导的rpgr x连锁视网膜变性的基因编辑治疗方法
WO2026119796A1 (en) * 2024-12-05 2026-06-11 Beacon Therapeutics Limited Gene therapy vector

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006516027A (ja) * 2002-12-02 2006-06-15 ジェンベク、インコーポレイティッド 眼関連障害の治療用材料および治療方法
CN105120901A (zh) * 2012-07-11 2015-12-02 宾夕法尼亚大学托管会 Rpgr x染色体连锁视网膜退化的aav介导的基因治疗
JP5971661B2 (ja) * 2012-09-19 2016-08-17 国立大学法人 東京大学 神経活動依存的プロモータ活性を有するdna、及びこれを含むベクター
CN105980569A (zh) * 2013-08-05 2016-09-28 莱顿大学医学中心附属莱顿教学医院 重组aav-crumbs同源物组合物及治疗lca-8和进行性rp的方法
KR102281881B1 (ko) * 2013-12-06 2021-07-27 엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔 (인쎄름) 대상체의 망막 색소 상피에서 목적 폴리뉴클레오티드를 발현시키기 위한 방법 및 약학적 조성물
EP3132051B1 (en) * 2014-04-15 2019-03-20 Applied Genetic Technologies Corporation Codon optimized nucleic acid encoding a retinitis pigmentosa gtpase regulator (rpgr)
LT3137497T (lt) * 2014-05-02 2021-07-26 Genzyme Corporation Aav vektoriai, skirti tinklainės ir cns genų terapijai
US20160346359A1 (en) * 2015-05-01 2016-12-01 Spark Therapeutics, Inc. Adeno-associated Virus-Mediated CRISPR-Cas9 Treatment of Ocular Disease
GB201516066D0 (en) * 2015-09-10 2015-10-28 Young & Co Llp D Treatment of retinitis pigmentosa
CN109640949B (zh) * 2016-07-29 2022-11-25 加利福尼亚大学董事会 具有变异衣壳的腺相关病毒病毒体和其使用方法
KR20250023600A (ko) * 2017-06-30 2025-02-18 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 변이체 캡시드를 보유한 아데노-부속 바이러스 비리온 및 이의 사용 방법
AU2019216257B2 (en) * 2018-01-31 2025-11-20 Research Institute At Nationwide Children's Hospital Gene therapy for limb-girdle muscular dystrophy type 2C
TW202028225A (zh) * 2018-09-21 2020-08-01 英商夜星克有限公司 用於治療色素性視網膜炎之組合物及方法
CN115279421A (zh) * 2020-01-10 2022-11-01 坚固生物科技公司 用于联合疗法的病毒载体

Similar Documents

Publication Publication Date Title
JP2023036618A (ja) コロイデレミアの遺伝子治療に使用するためのaavベクター
JP2026027271A5 (cg-RX-API-DMAC7.html)
JP2022500066A5 (cg-RX-API-DMAC7.html)
JP2025179046A5 (cg-RX-API-DMAC7.html)
US20020045264A1 (en) Production of chimeric capsid vectors
AU2020331882B2 (en) Isolated modified VP1 capsid protein of AAV5
JP2021500922A5 (cg-RX-API-DMAC7.html)
US11141425B2 (en) Enhancing AAV-mediated transduction of ocular tissues with hyaluronic acid
US20220193207A1 (en) Compositions useful for treatment of pompe disease
JP2023540464A5 (cg-RX-API-DMAC7.html)
JP2020512822A5 (cg-RX-API-DMAC7.html)
EP3188762A1 (en) High isomerohydrolase activity mutants of mammalian rpe65
WO2021113634A1 (en) Transgene cassettes designed to express a human mecp2 gene
JP2022530095A5 (cg-RX-API-DMAC7.html)
JP2023509443A5 (cg-RX-API-DMAC7.html)
JP2021525531A5 (cg-RX-API-DMAC7.html)
CN109952114A (zh) 用于治疗醛脱氢酶缺乏的基因疗法
JP2024545186A5 (cg-RX-API-DMAC7.html)
JP2018526994A5 (cg-RX-API-DMAC7.html)
JP2024500786A5 (cg-RX-API-DMAC7.html)
JP2023535232A5 (cg-RX-API-DMAC7.html)
WO2024079661A1 (en) Atp7b gene therapy
US12415850B2 (en) Compositions and methods for regulating production of an antibody like protein and ribonucleic acid
EP4073087A1 (en) Recombinant adeno-associated viral vector for gene delivery
CN117003833A (zh) 肝脏特异性的腺相关病毒血清型及应用